Literature DB >> 7012409

The role of gastric glucagon immunoreactivity in pancreatectomized dogs.

S Ikei, K Mori, Y Sakamoto, J Ishii, O Watanabe, M Inoue, M Akagi.   

Abstract

Immunoreactive glucagon (IRG) or glucagon immunoreactivity is known to be increased in the plasma of insulin-deprived pancreatectomized dogs, most of it originating in the stomach. We attempted to clarify the extent to which gastric IRG is involved in glycogenolysis in the liver of insulin-deprived, pancreatectomized dogs. Mongrel dogs underwent total pancreatectomy. IRG levels in portal vein blood increased to 760 +/- 186 pg/ml on the 4th postoperative day while the insulin levels were negligible. On the 4th postoperative day some of the dogs underwent total gastrectomy. IRG levels in the portal vein blood of pancreatectomized dogs decreased from 760 +/- 186 pg/ml to 135 +/- 44 pg/ml one hour after gastrectomy. Glucose containing insulin was then infused into both pancreatectomized and pancreatectomized-gastrectomized grups of dogs. Glycogen synthesis in the liver during glucose and insulin infusion was much the same in both groups. However, glycogen degradation after glucose and insulin infusion was completely suppressed in pancreatectomized dogs without a stomach while pancreatectomized dogs alone showed marked glycogenolysis in the liver. No difference in portal IRI and blood sugar level was found in both groups while a marked difference in portal IRG were observed. These findings indicate that the IRG released from the stomach plays a significant role i glycogen metabolism in pancreatectomized dogs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7012409     DOI: 10.1007/bf02468757

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  14 in total

1.  Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs.

Authors:  I Valverde; R Dobbs; R H Unger
Journal:  Metabolism       Date:  1975-09       Impact factor: 8.694

2.  Specific determination of blood glucose with o-toluidine.

Authors:  A HYVARINEN; E A NIKKILA
Journal:  Clin Chim Acta       Date:  1962-01       Impact factor: 3.786

3.  Glucagon antibodies and their use for immunoassay for glucagon.

Authors:  R H UNGER; A M EISENTRAUT; M S McCALL; S KELLER; H C LANZ; L L MADISON
Journal:  Proc Soc Exp Biol Med       Date:  1959 Oct-Dec

4.  Two methods for the determination of glycogen in liver.

Authors:  J VAN DER VIES
Journal:  Biochem J       Date:  1954-07       Impact factor: 3.857

5.  Identification of glucagon in the gastrointestinal tract.

Authors:  H Sasaki; B Rubalcava; D Baetens; E Blazquez; C B Srikant; L Orci; R H Unger
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

6.  Characteristics of tissue IRGs in the dog.

Authors:  C B Srikant; K McCorkle; R H Unger
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

7.  Plasma glucose, insulin, pancreatic, and enteroglucagon levels in normal and depancreatized dogs.

Authors:  T Matsuyama; P P Foà
Journal:  Proc Soc Exp Biol Med       Date:  1974-10

8.  Increased "glucagon immunoreactivity" in plasma of totally depancreatized dogs.

Authors:  M Vranic; S Pek; R Kawamori
Journal:  Diabetes       Date:  1974-11       Impact factor: 9.461

9.  Identification of glucagon-producing cells (A cells) in dog gastric mucosa.

Authors:  D Baetens; C Rufener; B C Srikant; R Dobbs; R Unger; L Orci
Journal:  J Cell Biol       Date:  1976-05       Impact factor: 10.539

10.  Persistent pancreatic glucagon but not insulin response to arginine in pancreatectomized dogs.

Authors:  K Mashiter; P E Harding; M Chou; G D Mashiter; J Stout; D Diamond; J B Field
Journal:  Endocrinology       Date:  1975-03       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.